NY-KP-SANGHVI
23.8.2021 12:02:05 CEST | Business Wire | Press release
KP Sanghvi, the global licensee for Serena Williams Jewelry, is pleased to announce the international expansion of its Serena Williams Jewelry collection. Building upon its introduction in the United States this month, the brand will be vetting new global opportunities in additional markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005058/en/
Gautam Begani, COO of KP Sanghvi Jewelry stated, “It has been an absolute joy working with Serena and watching her inspire new fine jewelry collections that mirror her bold, yet playful, sense of style. We’re so excited about our new retail distribution with one of the largest specialty jewelers in the US. Our major next step is taking Serena’s diamond jewelry designs to a wider audience of her fans globally.”
Serena Williams added, “I love expressing myself through fashion. My diamond jewelry collection is a beautiful celebration of the strong women in my life and around the world. I’m so grateful for the opportunity for my designs to inspire people to love themselves, believe in themselves, and to bring a little sparkle and joy to special moments.”
The SWJ Collection focuses on three key design themes:
Unstoppable : Inspiring strength and resilience. This collection reflects Serena’s positive outlook on life, her determination, and the unstoppable resilience she embodies.
Believe, Be Great : Self-empowerment and individual expression. A reflection of Serena’s persona and the importance of believing in oneself to achieve one’s goals through words of affirmation like “queen ,” “great,” “inspire,” and “loved .”
By My Side : A celebration of mothers, daughters, aunties, and grandmothers, and the love we share... inspired by Serena and her daughter.
Serena Williams Jewelry includes over 60 sparkling rings, necklaces, earrings, and bracelets set in gold and sterling silver accented with brilliant, natural diamonds. Prices range from $99 to $999 USD depending on the metal and carat weight.
View the entire collection at www.serenawilliamsjewelry.com and read more at https://www.jckonline.com/editorial-article/zales-serena-williams-jewelry/
ABOUT K.P. SANGHVI AND SERENA WILLIAMS JEWELRY
Under the personal design guidance and oversight of Serena Williams, all Serena Williams Jewelry is expertly crafted by KP Sanghvi, one of the largest vertically integrated diamond companies in the world. As the worldwide licensee of the SWJ brand and with over 50 years of experience working with jewelry brands across the globe, the Sanghvi family places social responsibility at the forefront of their company values, along with integrity and quality craftsmanship.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210823005058/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom